LumibirdHAM:QTL -3.93%65 Interest Coverage is 5.89 as of Dec. 2025, which is 26% below its 10-year median of 7.99. GuruFocus rates HAM:QTL with a GF Score™ of 65/100 and a GF Value™ of €16.31 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 95 Medical Diagnostics & Research companies, Lumibird ranks worse than 71.58% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Lumibird's
Operating Income
for the
six
months ended in Dec. 2025 was €16.1 Mil. Lumibird's Interest Expense for the
six
months ended in Dec. 2025 was €-2.7 Mil.
Lumibird's interest coverage for the quarter that ended in Dec. 2025 was 5.89.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Lumibird's Interest Coverage or its related term are showing as below:
HAM:QTL'
s Interest Coverage Range Over the Past 10 Years
Min: 2.38 Med: 7.99 Max: 35.24
Current: 4.49
HAM:QTL's Interest Coverage is ranked worse than 71.58% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs HAM:QTL: 4.49
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Lumibird Interest Coverage Related Terms
Lumibird Interest Coverage Historical Data
* Premium members only.
The historical data trend for Lumibird's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HAM:QTL vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Lumibird's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumibird Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Lumibird's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumibird (HAM:QTL) has a Interest Coverage of 5.89 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lumibird and its competitors. This is 26% below median its historical median of 7.99. Over the past decade, Lumibird's Interest Coverage has ranged from 2.38 to 35.24. According to the industry distribution chart, Lumibird ranks #68 out of 95 companies in the Medical Diagnostics & Research industry, placing it in the top 71.6%.
Is Lumibird's Interest Coverage too high?
Lumibird's current Interest Coverage of 5.89 is 26% below median its 10-year median of 7.99. Over the past 10 years, this metric has ranged from a low of 2.38 to a high of 35.24. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. Lumibird's value of 5.89 is 34.9% below this industry median. Based on the distribution chart, Lumibird ranks #68 out of 95 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lumibird has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #68 out of 95 companies for Interest Coverage. This places Lumibird in the lower half of its industry. The industry median Interest Coverage is 9.05. Lumibird's value of 5.89 is 34.9% below this benchmark. Historically, Lumibird's own Interest Coverage has ranged from 2.38 to 35.24 over the past decade. While the company's 10-year median is 7.99 vs. the industry median of 9.05, Lumibird has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumibird's current Interest Coverage of 5.89 is 34.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lumibird and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumibird's current Interest Coverage is 5.89, which is 26% below median its own 10-year median of 7.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (HAM:QTL) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.31, compared to a current price of €23.25 — trading 42.6% above its estimated fair value. The current Interest Coverage is 5.89, which is 26% below median its 10-year median of 7.99 and 34.9% below the Medical Diagnostics & Research industry median of 9.05. Lumibird's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Lumibird (HAM:QTL), the current Interest Coverage is 5.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumibird (HAM:QTL) Overvalued in 2026?
Based on GuruFocus' analysis, Lumibird stock appears to be overvalued.
The current stock price of €23.25 is trading 42.6% above its estimated GF Value™ of €16.31.
GuruFocus considers Lumibird to be Significantly Overvalued.
Key valuation signals for HAM:QTL:
Interest Coverage: 5.89 (26% below median its 10-year median of 7.99)
GF Value™: €16.31 vs. price of €23.25 (42.6% above fair value)
Industry Position: 34.9% below the Medical Diagnostics & Research median (#68 of 95)
No single metric tells the full story. See the HAM:QTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
65GF Score
Get the complete analysis for HAM:QTL
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:QTL has been successfully added to your 
